ZA201704328B - Glucagon derivatives - Google Patents

Glucagon derivatives

Info

Publication number
ZA201704328B
ZA201704328B ZA2017/04328A ZA201704328A ZA201704328B ZA 201704328 B ZA201704328 B ZA 201704328B ZA 2017/04328 A ZA2017/04328 A ZA 2017/04328A ZA 201704328 A ZA201704328 A ZA 201704328A ZA 201704328 B ZA201704328 B ZA 201704328B
Authority
ZA
South Africa
Prior art keywords
glucagon derivatives
glucagon
derivatives
Prior art date
Application number
ZA2017/04328A
Other languages
English (en)
Inventor
Sung Youb Jung
Young Jin Park
Jong Suk Lee
Jae Hyuk Choi
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of ZA201704328B publication Critical patent/ZA201704328B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2017/04328A 2014-12-30 2017-06-26 Glucagon derivatives ZA201704328B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140193691A KR102418477B1 (ko) 2014-12-30 2014-12-30 글루카곤 유도체
PCT/KR2015/014481 WO2016108617A1 (en) 2014-12-30 2015-12-30 Glucagon derivatives

Publications (1)

Publication Number Publication Date
ZA201704328B true ZA201704328B (en) 2021-01-27

Family

ID=56284668

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/04328A ZA201704328B (en) 2014-12-30 2017-06-26 Glucagon derivatives

Country Status (18)

Country Link
US (3) US10513550B2 (cg-RX-API-DMAC10.html)
EP (1) EP3240802B1 (cg-RX-API-DMAC10.html)
JP (1) JP6758297B2 (cg-RX-API-DMAC10.html)
KR (1) KR102418477B1 (cg-RX-API-DMAC10.html)
CN (1) CN107250155B (cg-RX-API-DMAC10.html)
AR (1) AR103323A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015372767B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017013845A2 (cg-RX-API-DMAC10.html)
CA (1) CA2972001C (cg-RX-API-DMAC10.html)
EA (1) EA036479B1 (cg-RX-API-DMAC10.html)
IL (1) IL253001B (cg-RX-API-DMAC10.html)
MX (1) MX389593B (cg-RX-API-DMAC10.html)
PH (1) PH12017501205A1 (cg-RX-API-DMAC10.html)
SG (2) SG10201906912VA (cg-RX-API-DMAC10.html)
TW (1) TWI696631B (cg-RX-API-DMAC10.html)
UA (1) UA122967C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016108617A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201704328B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102291020B1 (ko) * 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
BR112021000933A2 (pt) * 2018-07-19 2021-04-27 D&D Pharmatech Inc. polipeptídeo, composição farmacêutica, método de preparação dela e método de prevenção ou tratamento de doenças
JP2025526148A (ja) 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型glp-1/グルカゴン受容体アゴニスト及びnpy2受容体アゴニストを含む組合せ治療

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR100389726B1 (ko) 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
KR20100020516A (ko) 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Glp-1-fc 융합 단백질 제제
CN106106497B (zh) 2007-07-27 2022-02-22 拜耳知识产权有限责任公司 三元活性化合物结合物
EP2187525B1 (en) 2007-08-07 2014-03-12 Fujitsu Limited Error detection device, and error correction/error detection decoding device and method
AU2008306190A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of bubuc and optionally EAA-MART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CA2728284C (en) * 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
FR2936441B1 (fr) 2008-09-26 2012-12-07 Rhodia Operations Article polyamide composite
AU2008365557A1 (en) * 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
JP5759976B2 (ja) 2009-03-20 2015-08-05 ハンミ・サイエンス・カンパニー・リミテッド 位置特異的な生理活性ポリペプチド結合体の調製方法
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
WO2011088837A1 (en) * 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN102576513B (zh) 2010-09-06 2014-11-12 松下电器产业株式会社 显示装置及其控制方法
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
EP2492749A1 (en) 2011-02-28 2012-08-29 Rohm and Haas Electronic Materials LLC Photoresist compositions and methods of forming photolithographic patterns
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
HRP20181591T1 (hr) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
TWI601744B (zh) 2011-06-17 2017-10-11 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン/glp−1レセプターコアゴニスト
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Tof-mra를 이용한 혈류특성 및 mr-신호강도구배(전단율) 유도방법
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA039082B1 (ru) 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
BR112015025464A2 (pt) * 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Also Published As

Publication number Publication date
IL253001B (en) 2022-04-01
EP3240802A4 (en) 2018-10-10
CA2972001A1 (en) 2016-07-07
US20200140515A1 (en) 2020-05-07
CN107250155A (zh) 2017-10-13
EA036479B1 (ru) 2020-11-16
KR102418477B1 (ko) 2022-07-08
TWI696631B (zh) 2020-06-21
CA2972001C (en) 2024-07-02
AR103323A1 (es) 2017-05-03
EP3240802A1 (en) 2017-11-08
PH12017501205A1 (en) 2017-10-18
IL253001A0 (en) 2017-08-31
KR20160082026A (ko) 2016-07-08
AU2015372767A1 (en) 2017-07-13
EA201791498A1 (ru) 2017-10-31
US11254724B2 (en) 2022-02-22
MX389593B (es) 2025-03-20
US20220025012A1 (en) 2022-01-27
US20180002395A1 (en) 2018-01-04
WO2016108617A1 (en) 2016-07-07
UA122967C2 (uk) 2021-01-27
JP6758297B2 (ja) 2020-09-23
JP2018505153A (ja) 2018-02-22
SG11201705130XA (en) 2017-07-28
AU2015372767B2 (en) 2020-07-16
SG10201906912VA (en) 2019-09-27
US10513550B2 (en) 2019-12-24
MX2017008715A (es) 2017-11-17
NZ771617A (en) 2024-09-27
US12018060B2 (en) 2024-06-25
TW201632546A (zh) 2016-09-16
CN107250155B (zh) 2021-08-10
BR112017013845A2 (pt) 2018-01-02
EP3240802B1 (en) 2021-07-21
NZ733649A (en) 2024-07-26
HK1246323A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
IL281375B (en) Glucagon derivatives have improved stability
IL253381A0 (en) History of h9-pyrrolo-dipyridine
GB2534439B (en) Packer
ZA201704602B (en) Dihydroindolizinone derivative
GB2533294B (en) Micro-hotplates
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
IL253001B (en) History of glucagon
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
SG11201608634RA (en) Cycloalkyl-linked diheterocycle derivatives
SI3097076T1 (sl) Novi derivati CYP-eikozanoida
IL248772A0 (en) A consequence of cyclohexyl pyridine
PT3228616T (pt) Derivados de piridina
GB2523854B (en) Circuitry
GB201421030D0 (en) Up